CIMBALA@BIONET-20.ARPA (03/13/88)
From: Jim.Cassatt@BIONET-20.ARPA
Return-Path: <@CUNYVM.CUNY.EDU:CZJ@NIHCU.BITNET>
Received: from CUNYVM.CUNY.EDU by BIONET-20.ARPA with TCP; Fri 11 Mar 88 18:13:41-PST
Received: from NIHCU.BITNET by CUNYVM.CUNY.EDU ; Fri, 11 Mar 88 21:15:18 EST
To: science-resources@bionet-20.arpa
From: CZJ%NIHCU.BITNET@CUNYVM.CUNY.EDU
Date: Fri, 11 Mar 88 21:13:50 EST
From the NIH guide to Grants and contracts 3/11/88. Enclosed is the
Table of Contents and items of interest.
Jim Cassatt
------------------------------------------------------------------
Vol. 17, No. 9, March 11, 1988
NOTICES
EXPEDITED REVIEW OF INVESTIGATOR-INITIATED AIDS RESEARCH
GRANT APPLICATIONS...................................(84/186)............... 1
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH
EXPEDITED REVIEW AND AWARD OF INVESTIGATOR-INITIATED AIDS
GRANT APPLICATIONS...................................(84/90, 189/284)....... 2
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
DATED ANNOUNCEMENTS (RFPs AND RFAs)
STUDIES OF CHEMICAL DISPOSITION IN MAMMALS (RFP).....(290/328).............. 3
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES
DIETARY SURVEYS AND FOOD COMPOSITION DATA (RFP)......(331/361).............. 4
National Cancer Institute
Index: CANCER
CRANIOFACIAL ANOMALIES RESEARCH CENTERS (RFA)........(364/492, 804/1084).... 4
National Institute of Dental Research
Index: DENTAL RESEARCH
INTERNATIONAL TRAINING GRANTS IN EPIDEMIOLOGY RELATED TO AIDS (RFA)......... 6
Fogarty International Center (495/581, 1087/1425)
Index: FOGARTY INTERNATIONAL CENTER
DEVELOPMENTAL RESEARCH IN SPECIAL POPULATIONS (RFA)..(584/719, 1428/1987)... 7
National Cancer Institute
Index: CANCER
NOTICES
The following two notices describe the main features of new procedures
intended to expedite the review of investigator-initiated AIDS research grant
applications. Additional details about these procedures will be published in
future issues of the NIH GUIDE. Applicant investigators, institutional
business officials, and others concerned with the submission of funding
requests for AIDS research are encouraged to watch the NIH GUIDE for
additional information.
EXPEDITED REVIEW OF INVESTIGATOR-INITIATED AIDS RESEARCH GRANT APPLICATIONS
P.T. 34; K.W. 0715120, 1014002
National Institutes of Health
The National Institutes of Health (NIH) has begun an expedited referral,
review, and award process for contract proposals and grant applications in
Acquired Immune Deficiency Syndrome (AIDS) research. Specific AIDS
initiatives that will be solicited, utilizing any of the current mechanisms
(contract, cooperative agreement or grant), will be announced at appropriate
times in the NIH Guide for Grants and Contracts. These announcements, which
in addition may also appear in selected scientific journals as well as the
Commerce Business Daily, will carry specific information regarding receipt
dates, review processes, and Institute requirements.
The plan for expediting the review of intended AIDS research also applies to
unsolicited investigator-initiated research project grant applications (R01
and R29). This process, which began in a limited way February 1, 1988,
extends throughout the various funding components of the NIH and is described
in this announcement: THE FOLLOWING APPLIES ONLY TO UNSOLICITED INVESTIGATOR
INITIATED R01 AND R29 GRANT APPLICATIONS ON AIDS RESEARCH.
This announcement establishes three new receipt dates for all unsolicited new
and competitive renewal AIDS research grant applications submitted to the
Division of Research Grants, NIH. The dates selected are JANUARY 2, MAY 1,
and SEPTEMBER 1 of each year, beginning MAY 1, 1988.
All applications received on or before these receipt deadlines, if determined
to be AIDS research, will undergo an accelerated review to award process
lasting approximately six months. In order to be considered for this
accelerated process, the following conditions must be met:
a. APPLICATIONS MUST BE DIRECTLY APPLICABLE TO AIDS (etiology, epidemiology,
natural history, diagnosis, treatment or prevention of AIDS, or the various
sequelae specifically associated with the syndrome. Preparation and screening
of anti-AIDS agents as well as vaccine development, including both preclinical
and clinical studies, are considered to be directly applicable). For example,
not all research applications examining various influences on T-lymphocytes
nor all applications dealing with retroviruses will be appropriate for this
expedited review process that will involve initial scientific merit review by
experts in AIDS. Applications only indirectly related to AIDS
will be evaluated by established initial review groups (study sections)
appropriate to the scientific discipline during regular NIH review cycles and
should not be submitted in response to the new AIDS receipt dates.
b. Applicants are requested to indicate "AIDS Research" in Block 2 of the
PHS-398. All other instructions for investigator-initiated research grant
applications, including the special requirements of the FIRST award (R29),
also apply to these applications.
c. The completed application, as described above, and 6 copies should be sent
to the following address; unique to AIDS applications:
DRG AIDS Coordinator
Division of Research Grants, NIH
Westwood Building, Room 9
Bethesda, Maryland 20892**
1
REVIEW AND AWARD SCHEDULE FOR AIDS APPLICATIONS
Receipt of Scientific Merit Second Level Review Earliest
AIDS Investigator- Review by AIDS by Institute Possible St
Initiated Applica- Study Sections Council or Board of Grant
tion in DRG
May 1 * July 10-20 Sept./Oct. Nov.
Sept. 1 * Nov. 15-25 Jan. Feb.
Jan. 2 * March 15-25 May June
* Because of the expedited review cycle, late applications will not be
accepted.
NOTE: In addition to the expedited review cycle outlined in this
announcement, AIDS applications may also be submitted for the regular research
grant receipt dates established for all applications (February 1, June 1,
October 1 for new applications and March 1, July 1, and November 1 for
competing continuation applications). Such submissions will undergo the usual
referral process, and be assigned to the most appropriate DRG study section
for that particular application. This alternative may be considered by any
investigator who decides that an expedited review cycle has no particular
advantage, because for example, current support for an ongoing AIDS research
effort continues for another year.
EXPEDITED REVIEW AND AWARD OF INVESTIGATOR-INITIATED AIDS GRANT APPLICATIONS
P.T. 34; K.W. 0715120, 1014002
Alcohol, Drug Abuse, and Mental Health Administration
INTRODUCTION
The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) has begun
an expedited referral, review, and award process for grant applications and
contract
proposals applicable to Acquired Immune Deficiency Syndrome (AIDS). Specific
AIDS initiatives that will be solicited utilizing any of the current
mechanisms (grant, contract, or cooperative agreement) will be announced at
appropriate times in the NIH Guide for Grants and Contracts or the Commerce
Business Daily. These announcements, which may also be published in
scientific journals, will carry specific information regarding receipt dates,
review processes, and Institute requirements.
In ADAMHA, the following procedures apply only to unsolicited (i.e., not in
response to an RFA) investigator-initiated research, research scientist
development/award, and research training grant applications (i.e., R, P, K, T,
and F activity codes).
APPLICATION RECEIPT, REVIEW, AND AWARD SCHEDULE
This notice establishes three new receipt dates for all unsolicited NEW AND
COMPETING renewal AIDS grant applications submitted to the Division of
Research Grants, NIH for review by ADAMHA. The special AIDS receipt, review,
and award cycle is outlined below:
Receipt of Scientific Second Level Earliest
AIDS Invest.- Merit Review Review Possible
Initiated Start of
Applications Grant
May 1* June/July Sept./Oct. Nov.
Sept. 1* Oct./Nov. Jan./Feb. Feb.
Jan. 2* Feb./Mar. May/June June
* Because of the expedited review cycle, late applications will not be
accepted.
ADAMHA will accept unsolicited investigator-initiated new and competing
renewal AIDS applications only on the special AIDS receipt dates. ADAMHA will
not accept AIDS applications for the regular PHS receipt dates (June 1,
October 1, and February 1). Applications received on or before the regular
PHS receipt deadlines, if determined to be applicable to AIDS, will be held
2
for the next special AIDS review cycle. All applications determined to be
applicable to AIDS will undergo an accelerated review to award process lasting
approximately six months.
In order to be considered for this accelerated process, applications must be
applicable to AIDS. (The National Institute on Alcohol Abuse and Alcoholism
supports research on all issues pertinent to alcohol and AIDS including the
potential modification of normal host defense mechanisms against HIV by
alcohol, the contribution of alcohol to risk-taking behavior directly related
to HIV acquisition (and the prevention of such behaviors), and the impact of
alcohol in altering the efficacy of treatment for HIV or opportunistic disease
consequent to AIDS. The National Institute on Drug Abuse supports research on
all aspects of drug abuse and AIDS, including
a wide range of subjects from the effects of illicit drugs on the immune
system to the treatment, prevention/ intervention of AIDS in populations at
special risk, e.g., intravenous drug abusers. The National Institute of
Mental Health supports research on the neuropsychiatric and neuropsychological
aspects of AIDS and AIDS dementia; research on the biopsychosocial aspects of
stress and immune function as related to HIV infection; and psychosocial
research on high-risk behaviors and strategies for motivating behavior change
in populations at high risk for AIDS.)
APPLICATION SUBMISSION INSTRUCTIONS
1. Applicants will be responsible for submitting an original grant
application form PHS 398 (Rev. 9/86) and 6 legible copies. Fellowship
applicants should submit an original application form PHS 416-1 (Rev. 6/85)
and 2 legible copies.
2. Applicants are requested to indicate "AIDS Research" in Block 2 of the PHS
398 (Block 3 of the PHS 416-1) and on the container used to mail the
application. All other instructions for investigator-initiated research,
research scientist development/award, and research training applications,
including the special requirements of the FIRST award (R29), also apply to
these applications.
3. The completed application, as described above, and 6 copies (2 copies for
fellowships) should be sent to the following address which is unique to AIDS
applications:
DRG AIDS Coordinator
Division of Research Grants, NIH
Westwood Building, Room 9
Bethesda, Maryland 20892**
-------